CPT2 and breast carcinoma: During the last decade, carnitine palmitoyltransferase I (CPT1) has been identified as a potential therapeutic target for a growing list of cancers that include breast cancer, prostate cancer, glioblastoma, colon cancer, gastric cancer, myeloma, and others [1–6].